zinc gluconate

Phase 3Small molecule

zinc gluconate is one of 52 small molecule programs targeting Carcinoma, Non-Small-Cell Lung. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Carcinoma, Non-Small-Cell LungActive, not recruiting

Noise-Induced Hearing LossActive, not recruiting

Olfactory DysfunctionNot yet recruiting

Prediabetic StateRecruiting

Carcinoma, Non-Small-Cell LungPhase 2

Active, not recruiting

Noise-Induced Hearing LossPreclinical

Active, not recruiting

Olfactory DysfunctionPhase 3

Not yet recruiting

Prediabetic StatePhase 3

Recruiting

Competition

Competitive Landscape

53 competitors in Carcinoma, Non-Small-Cell Lung

#DrugCompanyPhaseTrials

Keytruda

Merck & Co.

Phase 3

14 2

Rybrevant

Johnson & Johnson

Phase 3

13 3

Lazcluze

Johnson & Johnson

Phase 3

8 4

Imfinzi

AstraZeneca

Phase 3

7 5

Taxol

Teva

Phase 3

4 6

Paraplatin

AAvyxa

Phase 3

16 7

Tagrisso

AstraZeneca

Phase 3

3 8

Alimta

EEagle Pharmaceuticals, Inc.

Phase 3

13 9

Alimta

SShawn Eagle

Phase 3

11 10

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2028

ApprovedRecruiting

Prediabetic State

NCT05835037

Q2 2030

Phase 2Active, not recruiting

Carcinoma, Non-Small-Cell Lung

NCT06120140

Clinical

Trials by Indication[1]

Olfactory Dysfunction1 trial

The Effect of Platelet-rich Plasma Nasal Injection in the Treatment of Traumatic Olfactory Dysfunction

Not yet recruiting·TTaichung Veterans General Hospital·Phase 3·NCT06290219·80 enrolled

Low Birth Weight1 trial

Impact of Daily Zinc Supplementation to Infants Born With Low Birth Weight on Death and Severe Disease

Completed·SSociety for Applied Studies·Phase 3·NCT00495690·2,012 enrolled

APL1 trial

Effect of Zinc on Barrett's Metaplasia

Unknown status·MMain Line Health·Phase 1·NCT01984580·120 enrolled

Noise-Induced Hearing Loss1 trial

Improvement of Tinnitus After Oral Zinc on Patients With Noise-induced Hearing Loss

Completed·—·N/A·NCT02951715·20 enrolled

Hyperbilirubinemia1 trial

Efficacy of Zinc in Reducing Hyperbilirubinemia Among High Risk Neonates - A Double Blind Randomized Trial

Completed·—·Phase 1/2·NCT00692224·294 enrolled

5 more indications

Pneumonia1 trial

Zinc Intervention in Elderly for Prevention of Pneumonia

Completed·TTufts University·Phase 2/3·NCT05527899·105 enrolled

Cardiovascular1 trial

Zinc Effect on Inflammation and Cardiovascular Risk in HIV

Completed·UUniversity Hospitals Cleveland Medical Center·Phase 1·NCT05085834·95 enrolled

Carcinoma, Non-Small-Cell Lung1 trial

A Phase 2, Open-Label, Randomized Trial Evaluating the Impact of Enhanced Versus Standard Dermatologic Management on Selected Dermatologic Adverse Events Among Patients With Locally Advanced or Metastatic EGFR-Mutated NSCLC Treated First-Line With Amivantamab + Lazertinib

Active, not recruiting· Johnson & Johnson logo

Johnson & Johnson·Phase 2·NCT06120140·305 enrolled

Prediabetic State1 trial

Clinical and Nutrigenetic Assessment of Zinc in Participants With Prediabetes

Recruiting·UUniversity of Maryland, Baltimore·Approved·NCT05835037·200 enrolled

Unspecified1 trial

The Individual Therapy for Patients With Wilson's Disease

Unknown status·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 1·NCT03957720·400 enrolled

Sources

References

[1]
ClinicalTrials.gov — 10 trial records for zinc gluconate. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — zinc gluconate compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for zinc gluconate. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Johnson & Johnson company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Johnson & Johnson

zinc gluconate

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2028

Q2 2030

Trials by Indication[1]

Olfactory Dysfunction1 trial

Low Birth Weight1 trial

APL1 trial

Noise-Induced Hearing Loss1 trial

Hyperbilirubinemia1 trial

Pneumonia1 trial

Cardiovascular1 trial

Carcinoma, Non-Small-Cell Lung1 trial

Prediabetic State1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News